Monika Paroder

Monika Paroder

Auto-generated profile, based on publicly available information

Monika Paroder

Department of Pathology Montefiore Medical Center/Albert Einstein College of Medicine New York New York USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
HYHyun Ah Yoon
Hyun Ah Yoon
RBRachel Bartash
Rachel Bartash
IGInessa Gendlina
Inessa Gendlina
JRJohanna Rivera
Johanna Rivera
ANAntonio Nakouzi
Antonio Nakouzi
LPLiise-Anne Pirofski
Liise-Anne Pirofski
Convalescent plasma with severe acute respiratory disease coronavirus 2 (SARS-CoV-2) antibodies (CCP) may hold promise as a treatment for coronavirus disease 2019 (COVID-19). We compared the mortality and clinical outcome of patients with COVID-19 who received 200 mL of CCP with a spike protein IgG titer ≥ 1:2430 (median 1:47,385) within 72 hours of admission with propensity score–matched controls cared for at a medical center in the Bronx, between April 13 and May 4, 2020. Matching criteria for controls were age, sex, body mass index, race, ethnicity, comorbidities, week of admission, oxygen requirement, D-dimer, lymphocyte counts, corticosteroid use, and anticoagulation use. There was no difference in mortality or oxygenation between CCP recipients and controls at day 28. When stratified by age, compared with matched controls, CCP recipients less than 65 years had 4-fold lower risk of mortality and 4-fold lower risk of deterioration in oxygenation or mortality at day 28. For CCP recipients, pretransfusion spike protein IgG, IgM, and IgA titers were associated with mortality at day 28 in univariate analyses. No adverse effects of CCP were observed. Our results suggest CCP may be beneficial for hospitalized patients less than 65 years, but data from controlled trials are needed to validate this finding and establish the effect of aging on CCP efficacy.

5 March 2021 in Transfusion
Verified
Journal Article
Open access
PDF file
JSJames Szymanski
James Szymanski
LMLaurel Mohrmann
Laurel Mohrmann
JCJamal Carter
Jamal Carter
RNRandin Nelson
Randin Nelson
SCSweta Chekuri
Sweta Chekuri
MPMonika Paroder
Monika Paroder
Background Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has a variable clinical course with significant mortality. Early reports suggested higher rates of SARS‐CoV‐2 infection in patients with type A blood and enrichment of type A individuals among COVID‐19 mortalities. Study Design and Methods The study includes all patients hospitalized or with an emergency department (ED) visit who were tested for SARS‐CoV‐2 between March 10, 2020 and June 8, 2020 and had a positive test result by nucleic acid test (NAT) performed on a nasopharyngeal swab specimen. A total of 4968 patients met the study inclusion criteria, with a subsequent 23.1% (n = 1146/4968) all‐cause mortality rate in the study cohort. To estimate overall risk by ABO type and account for the competing risks of in‐hospital mortality and discharge, we calculated the cumulative incidence function (CIF) for each event. Cause‐specific hazard ratios (csHRs) for in‐hospital mortality and discharge were analyzed using multivariable Cox proportional hazards models. Results Type A blood was associated with the increased cause‐specific hazard of death among COVID‐19 patients compared to type O (HR = 1.17, 1.02–1.33, p = .02) and type B (HR = 1.32,1.10–1.58, p = .003). Conclusions Our study shows that ABO histo‐blood group type is associated with the risk of in‐hospital death in COVID‐19 patients, warranting additional inquiry. Elucidating the mechanism behind this association may reveal insights into the susceptibility and/or immunity to SARS‐CoV‐2.

20 September 2020 in medRxiv
Verified
Preprint
Open access
PDF file
JCJui Choudhuri
Jui Choudhuri
JCJamal Carter
Jamal Carter
RNRandin Nelson
Randin Nelson
KSKarin Skalina
Karin Skalina
MOMarika Osterbur-Badhey
Marika Osterbur-Badhey
JSJames Szymanski
James Szymanski
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cycle threshold (Ct) has been suggested as an approximate measure of initial viral burden. The relationship of initial Ct at hospitalization and patient mortality has not been thoroughly investigated. Methods and findings: We conducted a retrospective study of SARS-CoV-2 positive, hospitalized patients from 3/26/2020 to 8/5/2020 who had SARS-CoV-2 Ct data within 48 hours of admission (n=1044). Only patients with complete survival data discharged (n=774) or died in hospital (n=270), were included in our analysis. Laboratory, demographic, and clinical data were extracted from electronic medical records. Multivariable logistic regression was applied to examine the relationship of patient mortality with Ct values while adjusting for established risk factors. Ct was analyzed as continuous variable and subdivided into quartiles to better illustrate its relationship with outcome. Cumulative incidence curves were created to assess whether there was a survival difference in the setting of the competing risks of death versus patient discharge. Mean Ct at admission was higher for survivors (28.6, SD=5.8) compared to non-survivors (24.8, SD=6.0, P<0.001). Patients with lower Ct value on admission had higher odds ratio (0.91, CI 0.89-0.94, p32.9) had lower odds of in-hospital death (P<0.001). On comparing, Ct quartiles, mortality, BMI and GFR were significantly different (p<0.05) between the groups. The cumulative incidence of all-cause mortality and discharge was found to differ between Ct quartiles (Gray’s Test P<0.001). Conclusion: SARS-CoV-2 Ct was found to be an independent predictor of patient mortality. However, further study is needed on how to best clinically utilize such information given the result variation due to specimen quality, phase of disease, and the limited discriminative ability of the test. AUTHOR SUMMARY: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has effected the entire world, with approximately 23 million affected till date. Clinicians, researcher and scientists are making all efforts to identify ways of diagnosis, predicting outcome and treatment modalities. The polymerase chain reaction (rT-PCR) technology, is the standard test being used for the diagnosis and it gives an additional value known as “cycle threshold” (Ct), which is the number of PCR cycles required to cross the designated threshold and termed patient as positive for the infection. This Ct value is inverse of the viral load in the patient and has been studied as indicator of outcome of infection. In this study we have analyzed the Ct value as a predictor for mortality and compared it between different age and gender. We found the Ct value significantly different between those who survived and those who died due to the disease. However proper utilization of the Ct value needs further studies to be utilized in the clinical setting and guide decision making.

17 July 2021 in Transfusion
Verified
Journal Article
Closed access
PDF file
RNRandin Nelson
Randin Nelson
RMRichard Mathews
Richard Mathews
CPCarlo Palesi
Carlo Palesi
JCJamal Carter
Jamal Carter
JSJames Szymanski
James Szymanski
MPMonika Paroder
Monika Paroder

11 March 2021 in Transfusion
Verified
Journal Article
Closed access
PDF file
MBMohammad Barouqa
Mohammad Barouqa
JSJames Szymanski
James Szymanski
RNRandin Nelson
Randin Nelson
SJSebastian Jofre
Sebastian Jofre
MPMonika Paroder
Monika Paroder

5 October 2022 in Journal of Clinical Apheresis
Verified
Journal Article
Closed access
KKKevin Kuan
Kevin Kuan
JSJames Szymanski
James Szymanski
JCJamal Carter
Jamal Carter
RWRonald Walsh
Ronald Walsh
MPMonika Paroder
Monika Paroder